… access to clinical trial resources for Spanish- … obstacles to understanding treatment options and accessing … for culturally sensitive clinical trial education. This multimedia … addition to arthritis and autoimmune disorders, GHLF supports dermatology, …

… treating a variety of conditions, from diabetes and autoimmune disorders … ways to treat it — from medication to psychosocial interventions … The University of Washington developed the “collaborative care model … get them started on treatment.” While mental health …

… in research and development, supportive government … on neurology and autoimmune disorders, efforts to reduce … pharmacies, and higher demand for both oral and injectable medications … treatments. Download a free sample of the guillain-barre syndrome drugs …

… transplant rejection and autoimmune diseases, today announced the … Pharmaceuticals CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing … .S. Food and Drug Administration, European Medicines … respect to the treatment of antibody-mediated …

… cancer drug ceralasertib failed a Phase 3 trial in … stopped responding to other medications. The regimen didn’t … slow recruitment pace in autoimmune disease suggests "increased competition … there are no approved treatments for dyskinetic cerebral palsy. …

… CD19, in development for autoimmune disease and hematologic malignancies … patients with rheumatologic autoimmune diseases have been encouraging … first month of treatment, with repopulating … partners, including Vertex Pharmaceuticals. CRISPR Therapeutics …

… treating autoimmune diseases Given encouraging efficacy and safety, the trial … A solid pharmacokinetic/pharmacodynamic relationship has … developing novel immunotherapies for cancer and autoimmune disease. … the Treatment of T Cell–Induced Autoimmune Diseases. …

… conducting the ALSTARS Trial, a Phase 2 … biotechnology company developing proprietary treatments focused on … neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction … FDA NEUROLOGY CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL …

… trial of ICP-488, a novel TYK2 inhibitor, for the treatment … ) is a chronic autoimmune disease characterized by skin lesions … psychological burden. Current treatment options are limited, … that demonstrated favorable pharmacokinetics and tolerability. InnoCare …

… biologic in multiple autoimmune disorders with patient-friendly … developing next-generation therapies to transform the treatment of severe autoimmune diseases … key drivers of autoimmune disease pathogenesis, this … of biotech and pharma executives who …